BioNTech says drug from OncoC4 partnership shows promise in

BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc was shown to shrink tumours in close to 30% of participants in a mid-stage lung cancer trial.

Related Keywords

Friederike Heine , Ludwig Burger , Reuters , Thomson Reuters Trust Principles , Merck Co Mrkn Keytruda , Thomson Reuters Trust , Rsbi Regulatory Oversight , Rhpi Drug Device Trials , Rhpi Regulatory , Biodrg , Cmpny , Ncncer , Drudev , Gen , Genhlt , Hea , Heca , Humdis , Immogy , Medreg , Mrch , Phag08 , Phar , Phar08 , Phar1 , Phmr , Privt , Publ , Regs , Sci , Ceeu , Weu , Gamers , Us , Europ , Ezc , Namer , Dude , Ef Business Future Of Health ,